Should I Buy ADUS? ADUS 2026 Analysis

Should You Buy Addus Homecare Corp (ADUS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

101.800

1 Day change

-0.66%

52 Week Range

127.720

Analysis Updated At

2026/01/28

Buy now for a long-term beginner portfolio. ADUS is trading near support (~106.65) after a bearish stretch, while fundamentals (25% YoY revenue growth in 2025/Q3) and Wall Street targets ($120–$140+, with a new $135 Buy initiation) support a favorable long-term setup. With no Intellectia buy signals today, this is not a “must-buy today for a trade,” but it is still a good long-term buy at current levels for an impatient investor who wants to get invested now.

Technical Analysis

Trend is currently bearish-to-stabilizing. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), signaling the broader downtrend is still in control. However, momentum is trying to base: MACD histogram is slightly positive (0.0207) though contracting, suggesting upside momentum is present but weakening. RSI_6 at ~30.4 is near oversold territory, consistent with selling pressure potentially becoming exhausted. Key levels: immediate support S1 ~106.65 (then S2 ~105.16). Pivot ~109.07 is the first reclaim level; above that, resistance sits near R1 ~111.48 and R2 ~112.97. Pre-market at ~107.9 sits below the pivot but close to support, which is a reasonable long-term entry zone. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Options positioning is bullish by open interest (put/call OI ratio 0.16 indicates far more call OI than put OI), while daily trading activity is neutral (put/call volume ratio 1.0 on very light volume). Implied volatility is moderate (30D IV ~27) with low IV rank (~7) / percentile (~34), suggesting options are not pricing an unusually large move. Net read: longer-horizon positioning leans bullish, but near-term options flow is not strongly directional.

Technical Summary

Sell

Buy

Positive Catalysts

Strong underlying demand tailwind: secular shift toward in-home care cited by multiple analysts.
Solid operational performance: 2025/Q3 delivered strong top-line growth (+25% YoY) and improved gross margin.
Analyst support: multiple Buy/Outperform ratings with targets up to ~$140 and a fresh Truist Buy initiation at $135, implying meaningful upside from ~
Potential M&A opportunity set (noted by RBC) in a fragmented market.
Next earnings catalyst: QDEC 2025 earnings on 2026-02-26 (after hours).

Neutral/Negative Catalysts

Technical trend still bearish (MA stack is negative), so the stock hasn’t clearly re-established an uptrend yet.
Medicaid funding cut concerns remain an overhang (explicitly referenced by BMO as a reason to stay less constructive for now).
Limited near-term narrative catalysts: no notable news flow in the past week.
Street dissent exists: Barclays remains Underweight with a $117 target, pointing to cost pressures (cost of services) limiting EBITDA upside.

Financial Performance

Latest quarter: 2025/Q3. Revenue rose to $362.3M (+25.02% YoY), Net Income increased to $22.85M (+13.32% YoY), and EPS grew to $1.24 (+12.73% YoY). Gross margin improved to ~31% (+1.21% YoY). Overall: strong top-line expansion with continued earnings growth and modest margin improvement—healthy long-term growth trends for a services-based healthcare operator.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend is net-positive. Since early November 2025, RBC and TD Cowen lifted targets to ~$139–$140 with Outperform/Buy views after Q3 results; Truist initiated coverage on 2026-01-07 with a Buy and $135 target, emphasizing a fragmented market and secular tailwinds. Offsetting views: BMO initiated Market Perform at $120 due to Medicaid funding cut concerns, and Barclays stayed Underweight (though raised target to $117). Wall Street pros: durable in-home care tailwinds, strong organic growth, M&A runway. Cons: reimbursement/Medicaid funding risk and cost pressure sensitivity. Influential trading check: Hedge funds and insiders are neutral recently; no congress trading data available in the last 90 days (no reported politician activity).

7 Analyst Rating

Wall Street analysts forecast ADUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADUS is 133 USD with a low forecast of 117 USD and a high forecast of 147 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

1 Sell

Moderate Buy

Current: 102.480

Low

117

Averages

133

High

147

Current: 102.480

Low

117

Averages

133

High

147

Truist

Clarke Murphy

Buy

initiated

$135

AI Analysis

2026-01-07

Reason

Truist

Clarke Murphy

Price Target

$135

AI Analysis

2026-01-07

initiated

Buy

Reason

Truist analyst Clarke Murphy initiated coverage of Addus HomeCare with a Buy rating and $135 price target. The company is a leader in a "fragmented market with plenty of opportunity," the analyst tells investors in a research note. The firm says Addus will benefit from secular tailwinds from the more toward alternative sites. It believes the company has a strong earnings outlook with a favorable risk/reward at current levels.

BMO Capital

Market Perform

initiated

$120

2025-11-12

Reason

BMO Capital

Price Target

$120

2025-11-12

initiated

Market Perform

Reason

BMO Capital initiated coverage of Addus HomeCare with a Market Perform rating and $120 price target. The firm says it will look to get more constructive on the shares when concerns around Medicaid funding cuts start to ease. It remains positive on the longer-term macro shift toward in-home care, and Addus HomeCare's positioning.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ADUS

Unlock Now

ADUS Should I Buy

ADUS Should I Buy

Should You Buy Addus Homecare Corp (ADUS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch